Off-label uses of trazodone: a review

Bibliography

• Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr 2009;14(10):536-46
   PubMed Web of Science ®Google Scholar
• Lehmann HE, Ban TA, Schwartz GV. Psychotherapeutic profile of a new psychoactive drug trazodone (AF-1161). Int Pharmacopsychiatry 1975;10(1):42-53
   PubMedGoogle Scholar
• Roccatagliata G, Abbruzzese G, Albano C, Trazodone by intravenous infusion in 1977 in depressions secondary to organic disease. Int Pharmacopsychiatry 1977;12(2):72-9
   PubMedGoogle Scholar
• Kellams JJ, Klapper MH, Small JG. Trazodone, a new antidepressant: efficacy and safety in endogenous depression. J Clin Psychiatry 1979;40(9):390-5
   PubMedGoogle Scholar
• Wheatley D. Trazodone in depression. Int Pharmacopsychiatry 1980;15(4):240-6
   PubMedGoogle Scholar
• Brogden RN, Heel RC, Speight TM, Trazodone: a review of pharmacological properties and therapeutic use ITS in depression and anxiety. Drugs 1981;21(6):401-29
   PubMed Web of Science ®Google Scholar
• Van de Merwe TJ, Silverstone T, Ankier SI, A double-blind non-crossover placebo-controlled study of trazodone Between group comparison and amitriptyline on cardiovascular function in major depressive disorder. Psychopathology 1984;17(Suppl 2):64-76
   PubMedGoogle Scholar
• Prien RF, Blaine JD, Levine J. Antidepressant drug therapy: the role of the new antidepressants. Hosp Community Psychiatry 1985;36(5):513-16
   PubMedGoogle Scholar
• Williams GO. Management of depression in the elderly. Prim Care 1989;16(2):451-74
   PubMedGoogle Scholar
• Debus JR, Rush AJ, Himmel C, Fluoxetine versus trazodone in the treatment of outpatients with major depression. J Clin Psychiatry Weissenburger 1988;49(11):422-6
   PubMedGoogle Scholar
• Perry PJ, Garvey MJ, Kelly MW, A comparative trial of fluoxetine versus trazodone in outpatients with major depression. J Clin Psychiatry 1989;50(8):290-4
   PubMed Web of Science ®Google Scholar
• Haria M, Fitton A, McTavish D. Trazodone. ITS A review of pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 1994;4(4):331-55
   PubMed Web of Science ®Google Scholar
• Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord 1996;41(3):201-10
   PubMed Web of Science ®Google Scholar
• De Jonghe F, Swinkels JA. The safety of antidepressants. Drugs 1992;43(Suppl 2):40-6; discussion 46-47
   PubMedGoogle Scholar
• Salzman C. Pharmacologic treatment of depression in the elderly. J Clin Psychiatry 1993;54(Suppl):23-8
   PubMedGoogle Scholar
• Thas ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 1999;60(Suppl 17):28-31; discussion 46-48
   PubMedGoogle Scholar
• Nierenberg AA, Cole JO, Glass L. Possible trazodone potentiation of fluoxetine: a case series. J Clin Psychiatry 1992;53(3):83-5
   PubMedGoogle Scholar
• Michael A, O'Donnell EA. Sexual dysfunction induced-fluoxetine reversed by trazodone. Can J Psychiatry 2000;45(9):847-8
   PubMedGoogle Scholar
• Stryjer R, Spivak B, Strous RD, Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: a preliminary open-label study. Clin Neuropharmacol 2009;32(2):82-4
   PubMed Web of Science ®Google Scholar
• Florkowski A, Gruszczynski W, Gałecki P, Trazodone and venlafaxine in treatment of depressive disorders. Pol Merkur Lekarski 2005;18(107):556-9
   PubMedGoogle Scholar
• Kasper S, Olivieri L, Di Loreto G, A comparative, randomized, double-blind study of trazodone prolonged-release and paroxetine in the treatment of major depressive disorder patients with. Curr Med Res Opin 2005;21(8):1139-46
   PubMed Web of Science ®Google Scholar
• Munizza C, Olivieri L, Di Loreto G, A comparative, randomized, double-blind study of trazodone prolonged- release and sertraline in the treatment of major depressive disorder. 2006;22(9):1703-13
   Google Scholar
• Papakostas GI, Fava M. A meta-analysis of clinical trials comparing the serotonin (5HT) -2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Psychiatry 2007;22:444-7
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Rozova A, Gossen ER, The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia and suicidality in major depressive disorder. Psychopharmacol Bull 2009;42(4):5-22
   PubMedGoogle Scholar
• Frecska E. Trazodone – it's multifunctional mechanism of action and clinical use. Neuropsychofarmacol Hung 2010;12(4):477-82
   PubMedGoogle Scholar
• Extended-release trazodone (Oleptro) for depression. Med Lett Drugs Ther 2010;52(1351):91-2
   PubMedGoogle Scholar
• Li TC, Su PY, Chiu HW, Trazodone in major depressive disorder ameliorates nightmares. J Neuropsychiatry Clin Neurosci 2011;23(1):E4
   Google Scholar
• Newton R. The side effect profile of trazodone in comparison to an active control and placebo. J Clin Psychopharmacol 1981;1:89S-93S
   Google Scholar
• Fink HA, MacDonald R, Rutks IR, Trazodone for erectile dysfunction: a systematic review and meta -analysis. BJU Int 2003;92(4):441-6
   PubMed Web of Science ®Google Scholar
• Jayaram G, Rao P. Safety of trazodone as a sleep agent of inpatients. Psychosomatics 2005;46(4):367-9
   PubMedGoogle Scholar
• Rausch JL, Pavlinac DM, Newman PE. Complete heart block following a single dose of trazodone. Am J Psychiatry 1984;141(11):1472-3
   PubMedGoogle Scholar
• Zitron E, Kiesecker C, Scholz E, Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone. Naunyn Schmiedebergs Arch Pharmacol 2004;370(2):146-56
   PubMedGoogle Scholar
• Service JA, Waring WS. QT Prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone. Clin Toxicol (Phila) 2008;46(1):71-3
   PubMed Web of Science ®Google Scholar
• Ancoli- Israel S. Insomnia in the eldery: a review for the primary care practitioner. Sleep 2000;23(Suppl 1):S23-30
   Google Scholar
• Pollak CP, Perlick D, Linsner JP, Sleep problems in the community elderly as predictors of death and nursing home placement. J Community Health 1990;15:123-35
   PubMedGoogle Scholar
• McCall WV. Sleep in the elderly: burden, diagnosis and treatment. Prim Care Companion J Clin Psychiatry 2004;6(1):9-20
   PubMedGoogle Scholar
• Montgomery I, Oswald I, Morgan K, Enhances sleep in subjective quality trazodone but not in objective duration. Br J Clin Pharm 1983;16:139-44
   PubMed Web of Science ®Google Scholar
• Wheatley D. Trazodone: alternative dose regimens and sleep. Pharmaterapeutica 1984;3(9):607-12
   PubMedGoogle Scholar
• Scharf MB, Sachais BA. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry 1990;51(Suppl):13-17
   PubMedGoogle Scholar
• Nierenberg AA, Adler LA, Peselow E, Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994;151(7):1069-72
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr, Dornseif BE, Pultz JA, Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry 1991;52(7):294-9
   PubMed Web of Science ®Google Scholar
• Kallepalli BR, Bhatara VS, Fogasa BS, Trazodone is only Slightly faster than fluoxetine in relieving insomnia in adolescents with depressive disorders. J Child Adolesc Psychopharmacol 1997;7(2):97-107
   PubMedGoogle Scholar
• Haffmans PM, Vos MS. The effects of trazodone on sleep induced by brofaromine disturbances. Eur Psychiatry 1999;14(3):167-71
   PubMedGoogle Scholar
• Wichniak A, Wierzbicka A, Sobanska A, The effectiveness of treatment with trazodone in Patients with primary insomnia without and with prior history of hypnotics use. Pol Merkur Lekarski 2007;23(133):41-6
   PubMedGoogle Scholar
• Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry B 2002;26(2):249-60
   PubMedGoogle Scholar
• Camargos EF, Pandolfi MB, Freitas MP, Trazodone for the treatment of sleep disorders in dementia: an open-label, observational study and review. Arq Neuropsiquiatr 2011;69(1):44-9
   PubMedGoogle Scholar
• Warner MD, Dorn MR, Peabody CA. Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry 2001;34(4):128-31
   PubMed Web of Science ®Google Scholar
• Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005;66(4):469-76
   PubMed Web of Science ®Google Scholar
• Gale CK. The treatment of Generalised anxiety disorder. A systematic review. Panminerva Med 2002;44(4):283-6
   PubMed Web of Science ®Google Scholar
• Rickels K, Downing R, Schweizer E, Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Psychiatry 1993;50(11):884-95
   PubMedGoogle Scholar
• Charney DS, Woods SW, Goodman WK, Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry 1986;47(12):580-6
   PubMed Web of Science ®Google Scholar
• Mavissakalian M, Perel J, Bowler K, Trazodone in the treatment of panic disorder and agoraphobia with panic attacks. Am J Psychiatry 1987;144(6):785-7
   PubMedGoogle Scholar
• Hertzberg MA, Feldman ME, Beckham JC, Trial of trazodone for posttraumatic stress disorder using multiple baseline group design. J Clin Psychopharmacol 1996;16(4):294-8
   PubMed Web of Science ®Google Scholar
• Maher MJ, Rego SA, Asnis GM. Sleep Disturbances in Patients with post-traumatic stress disorder: epidemiology, impact and approaches to management. CNS Drugs 2006;20(7):567-90
   PubMed Web of Science ®Google Scholar
• Pigott TA, L'Heureux F, Rubenstein CS, A double-blind, placebo-controlled study of trazodone in patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992;12(3):156-62
   PubMedGoogle Scholar
• Prasad A. Efficacy of trazodone as an anti obsessional agent. Biochem Pharmacol Behave 1985;22(2):347-8
   PubMed Web of Science ®Google Scholar
• Hermesh H, Aizenberg D, Munitz H. Trazodone treatment in clomipramine-resistant obsessive-compulsive disorder. Clin Neuropharmacol 1990;13(4):322-8
   PubMedGoogle Scholar
• Marazziti D, Gemignani A, Bone L. Trazodone augmentation in OCD: a case series report. CNS Spectr 1999;4(12):48-9
   PubMedGoogle Scholar
• Pope HG, Keck PE, McElroy SL, A placebo-controlled study of trazodone in bulimia nervosa. J Clin Psychopharmacol 1989;9(4):254-9
   PubMed Web of Science ®Google Scholar
• Morillas-Arques P, Ma Rodriguez-Lopez C, Molina-Barea R, Trazodone for the treatment of fibromyalgia: an open-label, 12-week study. BMC Musculoskelet Disord 2010;11:204
   PubMed Web of Science ®Google Scholar
• Lopez-Pousa S, Garre-Olmo J, Vilalta-Franch J, Trazodone for Alzheimer's disease: a naturalistic follow-up study. Arch Gerontol Geriatr 2008;47(2):207-15
   PubMed Web of Science ®Google Scholar
• Wilson RC. The use of low-dose trazodone in the treatment of painful diabetic neuropathy. podiatrist. J Am Med Assoc 1999;89(9):46
   Google Scholar
• Bacaltchuk J, Hay P. Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst Rev 2003(4):CD003391
   Google Scholar
• Solyom L, Solyom C, Ledwidge B. Trazodone treatment of bulimia nervosa. J Clin Psychopharmacol 1989;9(4):287-90
   PubMedGoogle Scholar
• Hudson JI, Pope HG Jr, Keck PE Jr, McElroy SL. Treatment of bulimia nervosa with trazodone: short-term response and long-term follow-up. Clin Neuropharmacol 1989;12(Suppl 1):S38-46; Discussion S47-9
   Google Scholar
• Rickels K, DeMartinis N, Rynn M, Mandos L. Pharmacologic strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol 1999;19(6 Suppl 2):12S-6S
   Google Scholar
• Ansseau M, De Roeck J. Trazodone in benzodiazepine dependence. J Clin Psychiatry 1993;54(5):189-91
   PubMedGoogle Scholar
• Roccatagliata G, Albano C, Maffini M, Alcohol withdrawal syndrome: treatment with trazodone. Int Pharmacopsychiatry 1980;15(2):105-10
   PubMedGoogle Scholar
• Janira L, Hadjichristos A, Buonanno A, Adjuvant trazodone in the treatment of alcoholism: an open study. Alcohol Alcohol 1998;33(4):362-5
   PubMedGoogle Scholar
• Le Bon O, Murphy JR, Staner L, Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations. J Clin Psychopharmacol 2003;23(4):377-83
   PubMed Web of Science ®Google Scholar
• Friedmann PD, Rose JS, Swift R, Trazodone for sleep disturbance after alcohol detoxification: a double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2008;32(9):1652-60
   PubMed Web of Science ®Google Scholar
• Friedmann PD, Herman DS, Freedman S, Treatment of sleep disturbance in alcohol recovery: a national survey of addiction medicine physicians. J Addict Dis 2003;22(2):91-103
   PubMed Web of Science ®Google Scholar
• Calandre EP, Morillas-Arques P, Barea-Molina R, Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. BMC Musculoskelet Disord 2011;12:95
   PubMed Web of Science ®Google Scholar
• Lebert F, Pasquier F, Petit H. Behavioral effects of trazodone in Alzheimer's disease. J Clin Psychiatry 1994;55(12):536-8
   PubMed Web of Science ®Google Scholar
• Simpson DM, Foster D. Improvement in organically disturbed behavior treatment with trazodone. J Clin Psychiatry 1986;47(4):191-3
   PubMedGoogle Scholar
• Houlihan DJ, Mulsant BH, Sweet RA, A naturalistic study of trazodone in the treatment of behavioral complications of dementia. Am J Geriatr Psychiatry 1994;2(1):78-85
   PubMed Web of Science ®Google Scholar
• Sultzer DL, Gray KF, Gunay I, A double-blind comparison of trazodone and haloperidol for treatment of Patients with agitation in dementia. Am J Geriatr Psychiatry 1997;5(1):60-9
   PubMed Web of Science ®Google Scholar
• Lebert F, Stekke W, Hasenbroekx C, Frontotemporal dementia: a randomized, controlled trial with trazodone. Dement Geriatr Cogn Disord 2004;17(4):355-9
   PubMed Web of Science ®Google Scholar
• Kitamura Y, Kudo Y, Imamura T. Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations. No To Shinkei 2006;58(6):483-8
   PubMedGoogle Scholar
• Martinon-Torres G, Fioravanti M, Grimley EJ. Trazodone for agitation in dementia. Cochrane Database Syst Rev 2004(4):CD004990
   Google Scholar
• Hayashi T, Yokota N, Takahashi T, Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study. Int Clin Psychopharmacol 1997;12(4):199-205
   PubMed Web of Science ®Google Scholar
• Decina P, Mukherjee S, Bocola V, Adjunctive trazodone in the treatment of negative Symptoms of schizophrenia. Hosp Community Psychiatry 1994;45(12):1220-3
   PubMedGoogle Scholar
• Ribosa-Nogue R, Pagonabarraga J, Kulisevsky J. Efficacy of trazodone in antipsychotic-induced akathisia resistant to conventional treatment. Parkinsonism Relat Disord 2012. [Epub ahead of print]
   Google Scholar
• Gulsun M, Doruk A. Mirtazapine-induced akathisia. J Clin Psychopharmacol 2008;28(4):467
   PubMed Web of Science ®Google Scholar
• Stryjer R, Rosenzcwaig S, Bar F, Trazodone for the treatment of acute neuroleptic-induced akathisia: a placebo-controlled, double-blind, crossover study. Clin Neuropharmacol 2010;33(5):219-22
   PubMedGoogle Scholar
• Hieber R, Dellenbaugh T, Nelson LA. Role of mirtazapine in the treatment of antipsychotic-induced akathisia. Ann Pharmacother 2008;42(6):841-6
   PubMedGoogle Scholar
• Wynchank D, Berk M. Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial. Hum Psychopharmacol 2003;18(4):271-5
   PubMedGoogle Scholar
• Gershon S. Chronic pain: hypothesized mechanism and rationale for treatment. Neuropsychobiology 1986;15(Suppl 1):22-7
   PubMedGoogle Scholar
• Davidoff G, Guarracini M, Roth E, Trazodone hydrochloride in the treatment of dysesthetic pain in traumatic myelopathy: a randomized, double-blind, placebo-controlled study. Pain 1987;29(2):151-61
   PubMedGoogle Scholar
• Goodkin K, Gullion CM, Agras WAS. A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome. J Clin Psychopharmacol 1990;10(4):269-78
   PubMedGoogle Scholar
• Tammiala-Salonen T, Forssell H. Trazodone in burning mouth pain: a placebo-controlled, double-blind study. Orofac J Pain 1999;13(2):83-8
   PubMedGoogle Scholar
• Meinhardt W, Schmitz PI, Kropman RF, Trazodone, a double blind trial for treatment of erectile dysfunction. Impot Res Int J 1997;9(3):163-5
   PubMedGoogle Scholar
• Costabile RA, Spevak M. Oral trazodone is not effective therapy for erectile dysfunction: a double-blind, placebo-controlled trial. J Urol 1999;161(6):1819-22
   PubMedGoogle Scholar
• Enzlin P, Vanderschueren D, Bonte L, Trazodone: a double-blind, placebo-controlled, randomized study effects of ITS in Patients with erectile dysfunction without major organic findings. Impot Res Int J 2000;12(4):223-8
   PubMed Web of Science ®Google Scholar
• Aydin S, Odabasi O, Ercan M, Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic sexual dysfunction evil. Br J Urol 1996;77(2):256-60
   PubMedGoogle Scholar
• Stryjer R, Spivak B, Strous RD, Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: a preliminary open-label study. Clin Neuropharmacol 2009;32(2):82-4
   PubMed Web of Science ®Google Scholar
• Galecki P, Florkowski A. Effectiveness of trazodone in the treatment of sexual dysfunctions. Pol Merkur Lekarski 2010;29(169):66-9
   PubMedGoogle Scholar
• Muoret C, Isaac M, Briley M. Problems associated with long-term treatment with selective serotonin reuptake inhibitors. J Psychopharmacol 2009;23(8):967-74
   PubMedGoogle Scholar
• Pazzagli M, Giovannini MG, Pepeu G. Trazodone increases extracellular serotonin levels in the frontal cortex of rats. Eur J Pharmacol 1999;383:249-57
   PubMed Web of Science ®Google Scholar
• Abi-Saab WM, Bubser M, Roth RH, Deutch AY. 5HT2 receptor regulation of extracellular GABA levels in the prefrontal cortex. Neuropsychopharmacology 1999;20:92-6
   PubMedGoogle Scholar
• Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 2007;113:296-320
   PubMed Web of Science ®Google Scholar
• Prapotnik M, Waschgler R, Konig P, Therapeutic drug monitoring of trazodone: are there pharmacokinetic interactions involving citalopram and fluoxetine? Int J Clin Pharmacol Ther 2004;42(2):120-4
   PubMedGoogle Scholar
• Maes M, Westenberg H, Vandoolaeghe E, Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine. J Clin Psychopharmacol 1997;17:358-64
   PubMed Web of Science ®Google Scholar